See also "HIV PREVENTION IN MATERNAL HEALTH SERVICES PROGRAMMING GUIDE"
Joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection.
The intended purpose of this compendium is to provide program managers, organizations, and policy makers with a menu of indicators to better “know their HIV epidemic/know their response” from a gender perspective. The indicators in the compendium are all either part of existing indicators used i...n studies or by countries or have been adapted from existing indicators to address the intersection of gender and HIV. The indicators can be measured through existing data collection and information systems (e.g. routine program monitoring, surveys) in most country contexts, though some may require special studies or research.
more
Training materials for healthcare workers
Este guião tem como objetivos melhorar a qualidade do aconselhamento a doentes com HIV/SIDA, providenciar meios para garantir uma avaliação psicossocial e identificar fatores de risco que contribuem para uma baixa adesão à TARV e estabeceler a ligação entre a unidade sanitária e a comunidade....
more
Une étude de terrain internationale réalisée par des théologiens et des experts de santé africains et allemands
National estimates have been developed every two years since 2003, led by the NCASC with close collaboration from a range of technical experts, partners and epidemiologists from the UNAIDS, WHO and FHI. This contains information about estimations of adult HIV prevalence.
The Panel recommendations on initial combination regimens for the antiretroviral therapy (ART)-naive, HIV-infected patients.
A rapid situation analysis in three districts
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more